-
-
Call more information
660-596-2224 -
The US Food and Drug Administration (FDA) has approved the opioid oxycodone (OxyContin, Purdue Pharma LP) for pediatric patients aged 11 to 16 years with pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. “We requested the manufacturer of the pain management drugOxyContin perform studies evaluating safety […]
Read MoreI thought this was interesting so I wanted to share this is for our pain docs. Young adult opioid users are often the victims of sexual violence, according to results of a survey of opioid users in New York City. Among 164 men and women aged 18 to 29 years reporting heroin and/or nonmedical prescription […]
Read MoreThe US Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. The FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, dipeptidyl peptidase-4 (DPP-4) […]
Read MoreIn carefully selected patients, minimally invasive surgery is enabling physicians to stop strokes in their tracks. As more patients undergo such procedures, physicians are debating the best way to anesthetise them. Should patients be put under general anaesthesia or should they undergo conscious sedation? In the September, 2015 issue of the Journal of Stroke and […]
Read MoreHospitals and other healthcare facilities should stop using the Symbiq Infusion System manufactured by Hospira because hackers could gain access to the device and give patients life-threatening overdoses or underdoses of drugs, the US Food and Drug Administration (FDA) announced today. Hospira has ceased making this line of computerized infusion pumps for unrelated reasons and […]
Read More